{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:25:44Z","timestamp":1773181544268,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd011160","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T00:00:00Z","timestamp":1481760000000}}],"reference-count":69,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011160.pub2","type":"journal-article","created":{"date-parts":[[2016,12,17]],"date-time":"2016-12-17T10:45:12Z","timestamp":1481971512000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia"],"prefix":"10.1002","volume":"2016","author":[{"given":"Ying","family":"Zhu","sequence":"first","affiliation":[{"name":"Xiangya Hospital, Central South University; Department of Ophthalmology; No. 87, Xiangya Road Changsha Hunan China 410008"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Zhang","sequence":"additional","affiliation":[{"name":"Eye and Ear Nose Throat Hospital, Shanghai Medical School, Fudan University; Department of Ophthalmology; No. 83, Fenyang Road Shanghai China 200032"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gezhi","family":"Xu","sequence":"additional","affiliation":[{"name":"Eye and Ear Nose Throat Hospital, Shanghai Medical School, Fudan University; Department of Ophthalmology; No. 83, Fenyang Road Shanghai China 200032"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Peng","sequence":"additional","affiliation":[{"name":"Linyi People's Hospital affiliated to Shandong University; Department of Gastroenterology; 27 Jie Fang Road Linyi Shandong China 276000"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,12,15]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD011160.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ajo.2009.10.010","article-title":"Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab - a randomized controlled trial","volume":"149","author":"Gharbiya","year":"2010","journal-title":"American Journal of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD011160.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1097\/IAE.0b013e31826956b7","article-title":"Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization","volume":"32","author":"Iacono","year":"2012","journal-title":"Retina"},{"issue":"6","key":"10.1002\/14651858.CD011160.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","article-title":"Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR Study","volume":"122","author":"Ikuno","year":"2015","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD011160.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archophthalmol.2009.408","article-title":"Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia","volume":"128","author":"Parodi","year":"2010","journal-title":"Archives of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD011160.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","article-title":"RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia","volume":"121","author":"Wolf","year":"2014","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD011160.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.ophtha.2011.07.029","article-title":"Myopic choroidal neovascularization","volume":"118","author":"Ruiz-Moreno","year":"2011","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD011160.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.ophtha.2013.03.006","article-title":"Intravitreal bevacizumab in myopic neovascular membranes: 24-month results","volume":"120","author":"Ruiz-Moreno","year":"2013","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD011160.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ophtha.2010.04.016","article-title":"Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial","volume":"118","author":"Heier","year":"2011","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD011160.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.ophtha.2013.06.010","article-title":"Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study","volume":"120","author":"Tufail","year":"2013","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD011160.pub2-BIB0010|cit10","first-page":"335","article-title":"Combined therapy with bevacizumab and photodynamic therapy for myopic choroidal neovascularization: a one-year follow-up controlled study","volume":"7","author":"Saviano","year":"2014","journal-title":"International Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD011160.pub2-BIB0011|cit11","unstructured":"NCT01716026 Establishment of the initial protocol with intravitreal bevacizumab for the treatment of choroidal neovascularization associated with high myopia:3 vs 1 clinicaltrials.gov\/ct2\/show\/NCT01716026"},{"key":"10.1002\/14651858.CD011160.pub2-BIB0012|cit12","unstructured":"NCT01809223 The safety and efficacy of conbercept in the treatment of choroidal neovascularization (CNV) secondary to high myopia clinicaltrials.gov\/ct2\/show\/NCT01809223"},{"key":"10.1002\/14651858.CD011160.pub2-BIB0013|cit13","unstructured":"NCT01922102 A 12-month, phase III, randomized, double-masked, multicenter, active-controlled study to evaluate the efficacy and safety of two individualized regimens of 0.5mg ranibizumab vs. verteporfin PDT in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia clinicaltrials.gov\/ct2\/show\/NCT01922102"},{"issue":"4","key":"10.1002\/14651858.CD011160.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0002-9394(14)75794-0","article-title":"Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy","volume":"118","author":"Adamis","year":"1994","journal-title":"American Journal of Ophthalmology"},{"issue":"22","key":"10.1002\/14651858.CD011160.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD011160.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/bjo.2009.166025","article-title":"Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation","volume":"94","author":"Baba","year":"2010","journal-title":"British Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD011160.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000320010","article-title":"Antivascular endothelial growth factor for choroidal neovascularization in pathologic myopia","volume":"46","author":"Battaglia Parodi","year":"2010","journal-title":"Developments in Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD011160.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00417-006-0472-6","article-title":"Pegaptanib for myopic choroidal neovascularization in a young patient","volume":"245","author":"Bennett","year":"2007","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD011160.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0161-6420(02)01998-X","article-title":"Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP report No. 3","volume":"110","author":"Blinder","year":"2003","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD011160.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/archopht.120.12.1644","article-title":"Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion","volume":"120","author":"Boyd","year":"2002","journal-title":"Archives of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD011160.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00006982-199010000-00002","article-title":"Photocoagulation\u00a0scar\u00a0expansion\u00a0after\u00a0laser therapy\u00a0for\u00a0choroidal neovascularization\u00a0in degenerative myopia","volume":"10","author":"Brancato","year":"1990","journal-title":"Retina"},{"issue":"6","key":"10.1002\/14651858.CD011160.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.ophtha.2011.02.039","article-title":"Primary\u00a0endpoint\u00a0results\u00a0of a\u00a0phase II study\u00a0of\u00a0vascular endothelial growth factor\u00a0trap-eye\u00a0in\u00a0wet age-related macular degeneration","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"issue":"20","key":"10.1002\/14651858.CD011160.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab\u00a0and\u00a0bevacizumab\u00a0for neovascular age-related macular degeneration","volume":"364","author":"\u00a0Martin","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD011160.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD011160.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1097\/IAE.0b013e3181b1bb1a","article-title":"Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia","volume":"29","author":"Cohen","year":"2009","journal-title":"Retina"},{"issue":"10","key":"10.1002\/14651858.CD011160.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1167\/iovs.06-0433","article-title":"Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study","volume":"47","author":"Costa","year":"2006","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"8","key":"10.1002\/14651858.CD011160.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/IAE.0b013e3182411cee","article-title":"Long-term results of photodynamic therapy for subfoveal choroidal neovascularisation with pathologic myopia","volume":"32","author":"Giansanti","year":"2012","journal-title":"Retina"},{"issue":"2","key":"10.1002\/14651858.CD011160.pub2-BIB0028|cit28","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"27","key":"10.1002\/14651858.CD011160.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011160.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/eye.2009.201","article-title":"Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration","volume":"24","author":"Gupta","year":"2010","journal-title":"Eye"},{"issue":"4","key":"10.1002\/14651858.CD011160.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0002-9394(02)01335-1","article-title":"Surgical treatment of subfoveal neovascularization in myopia: macular translocation vs surgical removal","volume":"133","author":"Hamelin","year":"2002","journal-title":"American Journal of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD011160.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1470-2045(04)01467-6","article-title":"Monoclonal antibodies as therapeutic agents for cancer","volume":"5","author":"Harris","year":"2004","journal-title":"Lancet Oncology"},{"issue":"11","key":"10.1002\/14651858.CD011160.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1001\/archopht.122.11.1616","article-title":"Surgical\u00a0removal\u00a0vs\u00a0observation\u00a0for\u00a0subfoveal\u00a0choroidal neovascularization, either\u00a0associated\u00a0with the\u00a0ocular\u00a0histoplasmosis\u00a0syndrome\u00a0or\u00a0idiopathic: II. Quality-of-life findings from a randomized clinical trial: SST Group H Trial: SST Report No. 10","volume":"122","author":"Hawkins","year":"2004","journal-title":"Archives of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD011160.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.ophtha.2009.11.003","article-title":"Long-term pattern of progression of myopic maculopathy: a natural history study","volume":"117","author":"Hayashi","year":"2010","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD011160.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/IAE.0b013e3182278bae","article-title":"Two-year outcomes of intravitreal bevacizumab for choroidal neovascularization in Japanese patients with pathologic myopia","volume":"32","author":"Hayashi","year":"2012","journal-title":"Retina"},{"key":"10.1002\/14651858.CD011160.pub2-BIB0036|cit36","unstructured":"Higgins JP Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD011160.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ajo.2008.03.010","article-title":"Clinical\u00a0characteristics\u00a0of\u00a0posterior\u00a0staphyloma\u00a0in\u00a0eyes\u00a0with\u00a0pathologic\u00a0myopia","volume":"146","author":"Hsiang","year":"2008","journal-title":"American Journal of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD011160.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1097\/IAE.0b013e318174417a","article-title":"Lacquer crack formation and choroidal neovascularization in pathologic myopia","volume":"28","author":"Ikuno","year":"2008","journal-title":"Retina"},{"issue":"1","key":"10.1002\/14651858.CD011160.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ajo.2009.08.008","article-title":"Two-year\u00a0visual\u00a0results\u00a0for\u00a0older\u00a0Asian\u00a0women\u00a0treated\u00a0with\u00a0photodynamic therapy\u00a0or\u00a0bevacizumab for\u00a0myopic\u00a0choroidal neovascularization","volume":"149","author":"Ikuno","year":"2010","journal-title":"American Journal of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD011160.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy","year":"2012","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD011160.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.ophtha.2006.04.022","article-title":"Prevalence and causes of low vision and blindness in a Japanese adult population: the Tajimi Study","volume":"113","author":"Iwase","year":"2006","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD011160.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/00006982-199818020-00004","article-title":"Lacquer cracks following laser treatment of choroidal neovascularization in pathologic myopia","volume":"18","author":"Johnson","year":"1998","journal-title":"Retina"},{"issue":"4","key":"10.1002\/14651858.CD011160.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ajo.2004.05.029","article-title":"Macular translocation with chorioscleral outfolding: 2-year results","volume":"138","author":"Kamei","year":"2004","journal-title":"American Journal of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD011160.pub2-BIB0044|cit44","first-page":"1929","article-title":"Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor","volume":"37","author":"Kvanta","year":"1996","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"4","key":"10.1002\/14651858.CD011160.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1345\/aph.1H316","article-title":"Bevacizumab for neovascular ocular diseases","volume":"41","author":"Lynch","year":"2007","journal-title":"Annals of Pharmacotherapy"},{"issue":"6","key":"10.1002\/14651858.CD011160.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","article-title":"Systemic\u00a0bevacizumab\u00a0(Avastin)\u00a0therapy\u00a0for\u00a0neovascular\u00a0age-related macular degeneration twelve-week\u00a0results\u00a0of an\u00a0uncontrolled\u00a0open-label\u00a0clinical study","volume":"112","author":"Michels","year":"2005","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD011160.pub2-BIB0047|cit47","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011230.pub2","article-title":"Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration","author":"Moja","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD011160.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1111\/j.1442-9071.2011.02684.x","article-title":"Anti-vascular endothelial growth factor for myopic choroidal neovascularization","volume":"40","author":"Ng","year":"2012","journal-title":"Clinical and Experimental Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD011160.pub2-BIB0049|cit49","first-page":"1368","article-title":"Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia","volume":"89","author":"Nguyen","year":"2005","journal-title":"British Journal of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD011160.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1136\/bjo.87.5.570","article-title":"Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia","volume":"87","author":"Ohno-Matsui","year":"2003","journal-title":"British Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD011160.pub2-BIB0051|cit51","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"14","key":"10.1002\/14651858.CD011160.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD011160.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bjo.85.9.1041","article-title":"Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients","volume":"85","author":"Ruiz-Moreno","year":"2001","journal-title":"British Journal of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD011160.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00417-010-1340-y","article-title":"Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome","volume":"248","author":"Ruiz-Moreno","year":"2010","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD011160.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.ophtha.2011.07.029","article-title":"Myopic choroidal neovascularization","volume":"118","author":"Ruiz-Moreno","year":"2011","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD011160.pub2-BIB0056|cit56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005139.pub3","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","author":"Solomon","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD011160.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/archopht.1983.01040010405011","article-title":"Prevalence of myopia in the United States","volume":"101","author":"Sperduto","year":"1983","journal-title":"Archives of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD011160.pub2-BIB0058|cit58","first-page":"281","article-title":"Therapeutic efficacy and safety of off-label use of bevacizumab for the treatment of neovascular diseases of the eye","volume":"44","author":"Sun","year":"2008","journal-title":"Chinese Journal of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD011160.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/eye.2011.302","article-title":"Visual function 5 years or more after macular translocation surgery for myopic choroidal neovascularisation and age-related macular degeneration","volume":"26","author":"Takeuchi","year":"2012","journal-title":"Eye"},{"issue":"3","key":"10.1002\/14651858.CD011160.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archopht.118.3.344","article-title":"Subretinal surgery for choroidal neovascularization in patients with high myopia","volume":"118","author":"Uemura","year":"2000","journal-title":"Archives of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD011160.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0161-6420(01)00544-9","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial - VIP report No. 1","volume":"108","author":"Verteporfin in Photodynamic Therapy Study Group","year":"2001","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD011160.pub2-BIB0062|cit62","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419.pub4","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema","author":"Virgili","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD011160.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00417-009-1285-1","article-title":"Bevacizumab for choroidal neovascularization secondary to pathologic myopia: is there a decline of the treatment efficacy after 2 years?","volume":"248","author":"Voykov","year":"2010","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD011160.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/IAE.0b013e31827d260a","article-title":"Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis","volume":"33","author":"Wang","year":"2013","journal-title":"Retina"},{"issue":"9","key":"10.1002\/14651858.CD011160.pub2-BIB0065|cit65","first-page":"2486","article-title":"Prevalence and risk factors for refractive errors in adult Chinese in Singapore","volume":"41","author":"Wong","year":"2000","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"7","key":"10.1002\/14651858.CD011160.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1134.e1","DOI":"10.1016\/j.ophtha.2006.01.035","article-title":"Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing Eye Study","volume":"113","author":"Xu","year":"2006","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD011160.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/bjo.2006.096776","article-title":"Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia","volume":"91","author":"Yamamoto","year":"2007","journal-title":"British Journal of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD011160.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0161-6420(03)00461-5","article-title":"Myopic choroidal neovascularization: a 10-year follow-up","volume":"110","author":"Yoshida","year":"2003","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD011160.pub2-BIB0069|cit69","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011160","article-title":"Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathologic myopia","author":"Zhu","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD011160.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T02:57:39Z","timestamp":1717642659000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011160.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,12,15]]},"references-count":69,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011160.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,15]]}}}